Among patients with psoriasis in high-impact sites, risankizumab achieves complete skin clearance through 2 years of treatment.
Acute Myeloid Leukemia (AML) is the most common acute leukemia in adults affecting 2-6 adults per 100,000k globally. With relapse rates as high as 50%, routine measurable residual disease (MRD) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results